Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

The Diversified Services industry as a whole closed the day down 1.1% versus the S&P 500, which was down 0.3%. Laggards within the Diversified Services industry included Kelly Services ( KELYB), down 1.8%, Wilhelmina International ( WHLM), down 6.0%, SmartPros ( SPRO), down 1.5%, Amrep ( AXR), down 2.7% and Bioanalytical Systems ( BASI), down 3.4%.

TheStreet Ratings Group would like to highlight 3 stocks that pushed the industry lower today:

Bioanalytical Systems ( BASI) is one of the companies that pushed the Diversified Services industry lower today. Bioanalytical Systems was down $0.05 (3.4%) to $1.42 on light volume. Throughout the day, 6,719 shares of Bioanalytical Systems exchanged hands as compared to its average daily volume of 12,400 shares. The stock ranged in price between $1.40-$1.42 after having opened the day at $1.41 as compared to the previous trading day's close of $1.47.

Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in North America, the Pacific Rim, Europe, and internationally. Bioanalytical Systems has a market cap of $11.9 million and is part of the services sector. Shares are down 32.6% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreet Ratings rates Bioanalytical Systems as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on BASI go as follows:

  • BASI's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 35.53%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Life Sciences Tools & Services industry and the overall market, BIOANALYTICAL SYSTEMS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • BIOANALYTICAL SYSTEMS INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past 2 years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, BIOANALYTICAL SYSTEMS INC swung to a loss, reporting -$0.15 versus $0.09 in the prior year.
  • Regardless of the drop in revenue, the company managed to outperform against the industry average of 5.1%. Since the same quarter one year prior, revenues slightly dropped by 3.1%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
  • 37.64% is the gross profit margin for BIOANALYTICAL SYSTEMS INC which we consider to be strong. Regardless of BASI's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 2.61% trails the industry average.

You can view the full analysis from the report here: Bioanalytical Systems Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

At the close, Amrep ( AXR) was down $0.14 (2.7%) to $5.01 on average volume. Throughout the day, 3,221 shares of Amrep exchanged hands as compared to its average daily volume of 3,100 shares. The stock ranged in price between $5.01-$5.14 after having opened the day at $5.08 as compared to the previous trading day's close of $5.15.

AMREP Corporation, through its subsidiaries, is engaged in media services and real estate businesses in the United States. Amrep has a market cap of $41.7 million and is part of the services sector. Shares are up 34.1% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreet Ratings rates Amrep as a sell. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself and poor profit margins.

Highlights from TheStreet Ratings analysis on AXR go as follows:

  • Reflecting the weaknesses we have cited, including the decline in the company's earnings per share, AXR has underperformed the S&P 500 Index, declining 6.35% from its price level of one year ago. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
  • The gross profit margin for AMREP CORP is rather low; currently it is at 19.00%. Regardless of AXR's low profit margin, it has managed to increase from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 1.45% trails the industry average.
  • The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Commercial Services & Supplies industry and the overall market, AMREP CORP's return on equity significantly trails that of both the industry average and the S&P 500.
  • AMREP CORP's earnings per share declined by 25.0% in the most recent quarter compared to the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past 2 years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, AMREP CORP continued to lose money by earning -$0.43 versus -$0.47 in the prior year.
  • AXR, with its decline in revenue, underperformed when compared the industry average of 3.6%. Since the same quarter one year prior, revenues fell by 20.6%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.

You can view the full analysis from the report here: Amrep Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Wilhelmina International ( WHLM) was another company that pushed the Diversified Services industry lower today. Wilhelmina International was down $0.34 (6.0%) to $5.37 on light volume. Throughout the day, 100 shares of Wilhelmina International exchanged hands as compared to its average daily volume of 900 shares. The stock ranged in price between $5.37-$5.37 after having opened the day at $5.37 as compared to the previous trading day's close of $5.71.

Wilhelmina International has a market cap of $33.3 million and is part of the services sector. Shares are down 5.3% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.